After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
AVDL belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Avadel Pharmaceuticals plc is $1.72B. A total of 2.32 million shares were traded on the day, compared to an average of 1.22M shares.
In the most recent transaction, MCHUGH THOMAS S bought 2,000 shares of AVDL for 14.50 per share on Jan 16 ’24. After the transaction, the Chief Financial Officer now owns 80,500 company shares. In a previous transaction on Dec 28 ’23, McCamish Mark Anthony sold 75,000 shares at 14.53 per share. AVDL shares that Director owns now total 67,025.
Among the insiders who bought shares, MCHUGH THOMAS S acquired of 2,000 shares on Aug 14 ’23 at a per-share price of $14.45. This resulted in the Chief Financial Officer holding 78,500 shares of AVDL after the transaction. In another insider transaction, McCamish Mark Anthony sold 28,975 shares at $14.93 per share on Aug 11 ’23. Company shares held by the Director now total 142,025.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, AVDL has a high of $18.01 and a low of $9.50.
As of this writing, AVDL has an earnings estimate of $Avadel Pharmaceuticals plc per share for the current quarter. EPS was calculated based on a consensus of Anavex Life Sciences Corp. estimates, with a high estimate of $GraniteShares 1.5x Long NVDA Da per share and a lower estimate of $GraniteShares 2x Long NVDA Dail.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. AVDL’s latest balance sheet shows that the firm has $157.22M in Cash & Short Term Investments as of fiscal 2021. There were $145.00M in debt and $21.00M in liabilities at the time. Its Book Value Per Share was $0.92, while its Total Shareholder’s Equity was $78.24M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AVDL is Buy with a score of 4.90.
